(NYSE: STVN) Stevanato Group Spa's forecast annual revenue growth rate of 5.57% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 12.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.19%.
Stevanato Group Spa's revenue in 2026 is $1,360,924,418.On average, 13 Wall Street analysts forecast STVN's revenue for 2026 to be $397,329,407,232, with the lowest STVN revenue forecast at $377,947,484,928, and the highest STVN revenue forecast at $414,591,431,784. On average, 10 Wall Street analysts forecast STVN's revenue for 2027 to be $438,515,992,128, with the lowest STVN revenue forecast at $412,471,534,032, and the highest STVN revenue forecast at $460,320,654,720.
In 2028, STVN is forecast to generate $487,576,482,960 in revenue, with the lowest revenue forecast at $452,446,748,784 and the highest revenue forecast at $519,072,106,704.